Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS). Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared to older patients in clinical practice. Methods: PANGAEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Albrecht, Holger, Haas, Judith, Klotz, Luisa, Lang, Michael, Lassek, Christoph, Schmidt, Stephan, Ettle, Benjamin, Schulze-Topphoff, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982917/
https://www.ncbi.nlm.nih.gov/pubmed/33763018
http://dx.doi.org/10.3389/fneur.2021.637107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982917/
https://www.ncbi.nlm.nih.gov/pubmed/33763018
http://dx.doi.org/10.3389/fneur.2021.637107

Ejemplares similares